Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 01, 2023

BUY
$0.17 - $0.39 $6,905 - $15,841
40,619 New
40,619 $8,000
Q4 2019

Feb 04, 2020

SELL
$4.5 - $8.1 $57,334 - $103,202
-12,741 Closed
0 $0
Q3 2019

Nov 20, 2019

BUY
$3.15 - $6.59 $40,134 - $83,963
12,741 New
12,741 $64,000

About NeuBase Therapeutics, Inc.


  • Ticker NBSE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,258,700
  • Description
  • NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...
More about NBSE
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.